News

Agrospheres Announces Major Commercial Development Agreement with FMC Corporation

AgroSpheres, a biotechnology company pioneering breakthroughs in sustainable crop protection and crop health, today announced the signing of a major collaboration with FMC Corporation (NYSE:FMC), a global leader in agriculture sciences. The long-term alliance represents a major milestone in launching AgroSpheres’ vertically integrated product pipeline. Powered by a recent $25M Series B funding round and construction of a new manufacturing facility, the Virginia startup is well-positioned to transition its portfolio of proprietary active ingredients to end-to-end commercial production.

The agreement will bolster FMC’s capabilities in Lepidoptera control and AgroSpheres’ speed to market for its RNA portfolio. Throughout the collaboration, AgroSpheres’ internally generated RNA targets will be used to deliver a wide range of highly potent and selective biomodalities.

“In a global market desperately in need of effective tools to combat resistance, FMC has shown foresight by investing in next-generation technologies and setting aggressive goals to meet demand for high-performance biologicals,” said Ameer Shakeel, Founder and CTO of AgroSpheres. “As leaders in bringing molecules to market, they are an ideal partner for AgroSpheres as we progress to comprehensive product development. We are excited to codevelop with the FMC team.”

“AgroSpheres’ scalable manufacturing and delivery technology got our attention, but once we took a closer look at their suite of proprietary actives, we saw significant value in a partnership,” said Dr. Seva Rostovtsev, Executive Vice President and Chief Technology Officer of FMC Corporation. “Integrating this technology into our world class insecticide portfolio will help diversify and complement our crop protection offerings.”

The technology and biomodality platform

RNA interference biomolecules have demonstrated great promise in the lab but have struggled to yield consistent results for commercial biological development. AgroSpheres’ patented AgriCell manufacturing technology offers the missing link with a highly scalable and cost-effective platform. AgriCell production of encapsulated biomolecules delivers enhanced stability, performance and targeted uptake in pests. AgroSpheres’ groundbreaking biomodality approach targets specific, yet diverse biological actions, efficiently multiplying product offerings and innovation.

“FMC is committed to finding sustainable and pollinator-friendly solutions for global insect control,” said Lisa Hoffman, PhD, Director of Development Biology and External Partnerships at FMC Corporation. “After an extensive review of RNA technologies, it was clear that AgroSpheres has the right capabilities to help us be successful in this space.”

Reese Blackwell, Chief Business Officer at AgroSpheres, underscored the company’s firm commitment to the rapid development of commercial biomodalities, aiming to provide growers with solutions that are both effective and environmentally friendly. He emphasized the need for next-generation products to address the challenges currently faced by biologicals to ensure broad farmer adoption.

“Like FMC, we aim to be at the forefront of biological input innovation,” said Blackwell. “Our development prioritizes efficacy, scalability and rapid market entry. Observing FMC’s impressive revenue generation from newly launched products over the past five years confirms that they are the perfect collaborator to expedite our pioneering technologies from the laboratory to the farm gate.”

Recent News

10/22/2025

Virginia Catalyst Announces Round 19 of Grant Funding

The Virginia Catalyst announced today that it is accepting letters of intent (LOI) for Grant Round 19 to fund the development and commercialization of life science projects that address major unmet needs for improving human health and advance Virginia’s economy. “We at the Virginia Catalyst are pleased to provide funding in support of the Governor’s

10/21/2025

SRI multi-party team selected as an awardee by ARPA-H to develop at-home screening for ≥30 types of cancers

SRI, along with research partners Foothold Labs and Triple Ring Technologies and commercial partner Beacon Dx Health, has been awarded up to $34 million from the Advanced Research Projects Agency for Health (ARPA-H) to develop technology as part of the POSEIDON (Platform Optimizing SynBio for Early Intervention and Detection in Oncology) program. This pioneering program

10/21/2025

Quoin Pharmaceuticals Announces U.S. FDA Grants Orphan Drug Designation for QRX003 in Netherton Syndrome

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its lead product candidate, QRX003, for the treatment of Netherton Syndrome. The designation follows previously granted Orphan